2017 UROLOGY MEDICARE UPDATES Table 1

Total Page:16

File Type:pdf, Size:1020Kb

2017 UROLOGY MEDICARE UPDATES Table 1 2017 UROLOGY MEDICARE UPDATES MEDICA L Ambulatory Surgery Center Payment System, Hospital Outpatient Prospective Payment System and Physician Fee Schedule Medicare has made some significant changes to its Ambulatory Surgery Center payment system (ASC) [Table 1], Hospital Outpatient Prospective Payment System (OPPS) [Table 2], and Physician Fee Schedule (PFS) for 2017. In the charts below, we have identified some of the most significant changes. We have chosen to focus on changes greater than or equal to $100 for ASC and OPPS from 2016 to 2017. There were no changes to the PFS that met this criterion. If you have questions about specific information in this document, or perhaps something you do not see in this document, please do not hesitate to contact our reimbursement team at 800.468.1379 or [email protected]. Table 1: Changes in Ambulatory Surgery Center Reimbursement for Procedures of Interest 2017 2016 Ambulatory Ambulatory Payment Difference Surgery Center Surgery Center CPT Code Procedural Description Fee Schedule Fee Schedule Percutaneous nephrostolithotomy or pyelostolithotomy, with or without $4,043.72 $5,926.16 ($1,882.44) 50080 dilation, endoscopy, lithotripsy, stenting, or basket extraction; up to 2 cm Percutaneous nephrostolithotomy or pyelostolithotomy, with or without $4,043.72 $5,926.16 ($1,882.44) 50081 dilation, endoscopy, lithotripsy, stenting, or basket extraction; over 2 cm Cystourethroscopy, with fulguration (including cryosurgery or laser $1,738.71 $1,254.53 $484.18 52240 surgery) and/or resection of; LARGE bladder tumor(s) Cystourethroscopy (including ureteral catheterization); with removal of $1,738.71 $1,254.53 $484.18 52320 ureteral calculus Cystourethroscopy (including ureteral catheterization); with 52325 fragmentation of ureteral calculus (eg, ultrasonic or electro-hydraulic $1,738.71 $1,254.53 $484.18 technique) Cystourethroscopy, with ureteroscopy and/or pyeloscopy; with removal $1,738.71 $1,254.53 $484.18 52352 or manipulation of calculus (ureteral catheterization is included) Cystourethroscopy, with ureteroscopy and/or pyeloscopy; with biopsy $1,738.71 $1,254.53 $484.18 52354 and/or fulguration of ureteral or renal pelvic lesion NOTE: This is not an all-inclusive list of procedural code changes. Table 2: Changes in Hospital Outpatient Reimbursement for Procedures of Interest 2017 2016 Hospital Hospital Payment Outpatient Outpatient Difference Payment Payment CPT Code Procedural Description Introduction of guide into renal pelvis and/or ureter with dilation to $2,541.49 $2,243.49 $298.00 50395 establish nephrostomy tract, percutaneous Placement of nephrostomy catheter, percutaneous, including diagnostic nephrostogram and/or ureterogram when performed, imaging guidance $1,643.96 $1,506.42 $137.54 50432 (eg, ultrasound and/or fluoroscopy) and all associated radiological supervision and interpretation Placement of nephroureteral catheter, percutaneous, including diagnostic nephrostogram and/or ureterogram when performed, imaging $1,643.96 $1,506.42 $137.54 50433 guidance (eg, ultrasound and/or fluoroscopy) and all associated radiological supervision and interpretation, new access Placement of ureteral stent, percutaneous, including diagnostic nephrostogram and/or ureterogram when performed, imaging guidance $2,541.49 $2,243.49 $298.00 50693 (eg, ultrasound and/or fluoroscopy), and all associated radiological supervision and interpretation; pre-existing nephrostomy tract Table 2 continues on next page Current Procedural Terminology © 2016 American Medical Association. All Rights Reserved. CI-BEI-UROMU-EN-RE-201701 Table 2: Changes in Hospital Outpatient Reimbursement for Procedures of Interest (continued) 2017 2016 Hospital Hospital Payment Outpatient Outpatient Difference Payment Payment CPT Code Procedural Description Placement of ureteral stent, percutaneous, including diagnostic nephrostogram and/or ureterogram when performed, imaging guidance 50694 (eg, ultrasound and/or fluoroscopy), and all associated radiological $2,541.49 $2,243.49 $298.00 supervision and interpretation; new access, without separate nephrostomy catheter Placement of ureteral stent, percutaneous, including diagnostic nephrostogram and/or ureterogram when performed, imaging guidance 50695 (eg, ultrasound and/or fluoroscopy), and all associated radiological $2,541.49 $2,243.49 $298.00 supervision and interpretation; new access, with separate nephrostomy catheter Laparoscopy, surgical; ureteroneocystostomy with cystoscopy and $4,197.36 $4,001.15 $196.21 50947 ureteral stent placement Cystotomy, with insertion of ureteral catheter or stent (separate $1,643.96 $1,506.42 $137.54 51045 procedure) Cystourethroscopy, with ureteral catheterization, with or without 52005 irrigation, instillation, or ureteropyelography, exclusive of radiologic $1,643.96 $1,506.42 $137.54 service Cystourethroscopy, with ureteral catheterization, with or without 52007 irrigation, instillation, or ureteropyelography, exclusive of radiologic $2,541.49 $2,243.49 $298.00 service; with brush biopsy of ureter and/or renal pelvis 52204 Cystourethroscopy, with biopsy(s) $1,643.96 $1,506.42 $137.54 Cystourethroscopy, with fulguration (including cryosurgery or laser 52224 surgery) or treatment of MINOR (less than 0.5 cm) lesion(s) with or $1,643.96 $1,506.42 $137.54 without biopsy Cystourethroscopy, with fulguration (including cryosurgery or laser $2,541.49 $2,243.49 $298.00 52234 surgery) and/or resection of; SMALL bladder tumor(s) (0.5 up to 2.0 cm) Cystourethroscopy, with fulguration (including cryosurgery or laser $2,541.49 $2,243.49 $298.00 52235 surgery) and/or resection of; MEDIUM bladder tumor(s) (2.0 to 5.0 cm) Cystourethroscopy, with fulguration (including cryosurgery or laser $3,482.54 $2,243.49 $1,239.05 52240 surgery) and/or resection of; LARGE bladder tumor(s) Cystourethroscopy, with removal of foreign body, calculus, or ureteral $1,643.96 $1,506.42 $137.54 52310 stent from urethra or bladder (separate procedure); simple Cystourethroscopy, with removal of foreign body, calculus, or ureteral $1,643.96 $1,506.42 $137.54 52315 stent from urethra or bladder (separate procedure); complicated Litholapaxy: crushing or fragmentation of calculus by any means in $2,541.49 $2,243.49 $298.00 52317 bladder and removal of fragments; simple or small (less than 2.5 cm) Cystourethroscopy (including ureteral catheterization); with removal of $3,482.54 $2,243.49 $1,239.05 52320 ureteral calculus Cystourethroscopy (including ureteral catheterization); with 52325 fragmentation of ureteral calculus (eg, ultrasonic or electro-hydraulic $3,482.54 $2,243.49 $1,239.05 technique) Cystourethroscopy, with insertion of indwelling ureteral stent (eg, $2,541.49 $2,243.49 $298.00 52332 Gibbons or double-J type) Table 2 continues on next page Current Procedural Terminology © 2016 American Medical Association. All Rights Reserved. CI-BEI-UROMU-EN-RE-201701 Table 2: Changes in Hospital Outpatient Reimbursement for Procedures of Interest (continued) 2017 2016 Hospital Hospital Payment Outpatient Outpatient Difference CPT Code Procedural Description Payment Payment Cystourethroscopy with insertion of ureteral guide wire through kidney to $2,541.49 $2,243.49 $298.00 52334 establish a percutaneous nephrostomy, retrograde Cystourethroscopy, with ureteroscopy and/or pyeloscopy; with removal $3,482.54 $2,243.49 $1,239.05 52352 or manipulation of calculus (ureteral catheterization is included) Cystourethroscopy, with ureteroscopy and/or pyeloscopy; with biopsy $3,482.54 $2,243.49 $1,239.05 52354 and/or fulguration of ureteral or renal pelvic lesion NOTE: This is not an all-inclusive list of procedural code changes. Disclaimer: The information provided herein reflects Cook’s understanding of the procedure(s) and/or device(s) from sources that may include, but are not limited to, the CPT, coding system; Medicare payment systems; commercially available coding guides; professional societies; and research conducted by independent coding and reimbursement consultants. This information should not be construed as authoritative. The entity billing Medicare and/or third party payers is solely responsible for the accuracy of the codes assigned to the services and items in the medical record. Cook does not, and should not, have access to medical records, and therefore cannot recommend codes for specific cases. When you are making coding decisions, we encourage you to seek input from the AMA, relevant medical societies, CMS, your local Medicare Administrative Contractor and other health plans to which you submit claims. Cook does not promote the off-label use of its devices. Current Procedural Terminology © 2016 American Medical Association. All Rights Reserved. CI-BEI-UROMU-EN-RE-201701 .
Recommended publications
  • Urology 1 Cystoscopes
    Urology 1 Cystoscopes 2 Urethrotomes 3 Resectoscopes 4 Uretero-Renoscopes 5 Nephroscopes 6 Lithotripsy (UreTron) 7 Laser Therapy 8 Small Caliber 9 Fluid Management 10 Accessories Richard Wolf Medical Instruments Corporation assumes no responsibility or liability for any errors or omissions in the content of this catalog. The information contained in this catalog is provided on an “as is” basis with no guarantees of completeness, accuracy, usefulness, or timeliness, and without warranties of any kind whatsoever, expressed or implied. 1777- 02.01-1118USA Cysto-Urethroscopes 8650 E-line design CYSTOSCOPES The E-line design guarantees optimum handling and safe, fatigue-free operation as well as a wide range of possible combinations. Basic Set for Cystoscopy Cysto-urethroscope sheath, 19.5 Fr. with obturator 8650.0341 Adapter with 1 instrument port 8650.264 Insert with Albarran deflector, 2 instrument ports 8650.204 Sterile universal sealing valve (pack of 5) 4712348 Viewing obturator 8650.724 Biopsy forceps Marburg 8650.614 Grasping forceps 8650.684 PANOVIEW telescope, 0° 8650.414 PANOVIEW telescope, 70° 8650.415 Otis urethrotome 8517.00 822.31 822.13 822.31 Flexible connector 822.13 Tray 8585030 1777- 02.01-1118USA 2 PANOVIEW Telescopes Overview CYSTOSCOPES Ø Viewing direction Color code Application mm 0° blue Standard 4 8650.414 12° orange Standard 4 8654.431 Standard 4 8654.422 30° red Long sheath 4 8668.433* 70° yellow Standard 4 8650.415 * Only 25° available. 1777- 02.01-1118USA 3 Cysto-Urethroscope 8650 for telescope 4 mm, 0°, 12°, 30°, 70° and adapters CYSTOSCOPES Sheaths and obturators Adapters Sheath incl.
    [Show full text]
  • Cystoscopy to Understand a Cystoscopy, It Is Helpful to Become Familiar with the Urinary System (Figure 1)
    Northwestern Memorial Hospital Patient Education TESTS AND PROCEDURES Cystoscopy To understand a cystoscopy, it is helpful to become familiar with the urinary system (Figure 1). The system’s main purpose is to remove urinary waste products from your body. Urine is produced by the kidneys, moves through the ureters and is stored in the bladder. The bladder is a balloon-like organ that stores urine. The urethra is the tube that carries urine from the bladder out of your body. If you have Figure 1. Urinary system any questions or concerns, Kidneys please ask your physician or nurse. Ureters Bladder Urethra A cystoscopy is a procedure that allows your physician to look at the inside of your urethra and bladder. A telescope-like instrument called a cystoscope is passed through your urethra into your bladder. During the procedure, your physician may also do the following, as needed: ■ Remove stones from your bladder or ureters ■ Place or remove a ureteral stent ■ Insert medication into your bladder ■ Remove small pieces of tissue for testing (biopsy) from your urinary tract A cystoscopy may be done in a physician’s office or in the hospital’s operating room (OR). Your physician will discuss which option is best for you. Preparation and procedure If the test is done in the OR, you will be asked to sign a written consent. The OR procedure and any special preparation will be explained to you. There may be some discomfort during the examination. Some patients may require sedation or anesthesia. Depending on the type of medication used for your procedure, you will be told if you need to stop eating and drinking before your procedure.
    [Show full text]
  • Urology Services in the ASC
    Urology Services in the ASC Brad D. Lerner, MD, FACS, CASC Medical Director Summit ASC President of Chesapeake Urology Associates Chief of Urology Union Memorial Hospital Urologic Consultant NFL Baltimore Ravens Learning Objectives: Describe the numerous basic and advanced urology cases/lines of service that can be provided in an ASC setting Discuss various opportunities regarding clinical, operational and financial aspects of urology lines of service in an ASC setting Why Offer Urology Services in Your ASC? Majority of urologic surgical services are already outpatient Many urologic procedures are high volume, short duration and low cost Increasing emphasis on movement of site of service for surgical cases from hospitals and insurance carriers to ASCs There are still some case types where patients are traditionally admitted or placed in extended recovery status that can be converted to strictly outpatient status and would be suitable for an ASC Potential core of fee-for-service case types (microsurgery, aesthetics, prosthetics, etc.) Increasing Population of Those Aged 65 and Over As of 2018, it was estimated that there were 51 million persons aged 65 and over (15.63% of total population) By 2030, it is expected that there will be 72.1 million persons aged 65 and over National ASC Statistics - 2017 Urology cases represented 6% of total case mix for ASCs Urology cases were 4th in median net revenue per case (approximately $2,400) – behind Orthopedics, ENT and Podiatry Urology comprised 3% of single specialty ASCs (5th behind
    [Show full text]
  • Clinical Significance of Cystoscopic Urethral Stricture
    UCSF UC San Francisco Previously Published Works Title Clinical significance of cystoscopic urethral stricture recurrence after anterior urethroplasty: a multi-institution analysis from Trauma and Urologic Reconstructive Network of Surgeons (TURNS). Permalink https://escholarship.org/uc/item/3f57n621 Journal World journal of urology, 37(12) ISSN 0724-4983 Authors Baradaran, Nima Fergus, Kirkpatrick B Moses, Rachel A et al. Publication Date 2019-12-01 DOI 10.1007/s00345-019-02653-6 Peer reviewed eScholarship.org Powered by the California Digital Library University of California World Journal of Urology https://doi.org/10.1007/s00345-019-02653-6 ORIGINAL ARTICLE Clinical signifcance of cystoscopic urethral stricture recurrence after anterior urethroplasty: a multi‑institution analysis from Trauma and Urologic Reconstructive Network of Surgeons (TURNS) Nima Baradaran1 · Kirkpatrick B. Fergus2 · Rachel A. Moses3 · Darshan P. Patel3 · Thomas W. Gaither2 · Bryan B. Voelzke4 · Thomas G. Smith III5 · Bradley A. Erickson6 · Sean P. Elliott7 · Nejd F. Alsikaf8 · Alex J. Vanni9 · Jill Buckley10 · Lee C. Zhao11 · Jeremy B. Myers3 · Benjamin N. Breyer2 Received: 13 December 2018 / Accepted: 24 January 2019 © Springer-Verlag GmbH Germany, part of Springer Nature 2019 Abstract Purpose To assess the functional Queryoutcome of patients with cystoscopic recurrence of stricture post-urethroplasty and to evaluate the role of cystoscopy as initial screening tool to predict future failure. Methods Cases with cystoscopy data after anterior urethroplasty in a multi-institutional database were retrospectively studied. Based on cystoscopic evaluation, performed within 3-months post-urethroplasty, patients were categorized as small-caliber (SC) stricture recurrence: stricture unable to be passed by standard cystoscope, large-caliber (LC) stricture accommodating a cystoscope, and no recurrence.
    [Show full text]
  • Cystoscopy Into the Bladder Via the Urethra, It Is About As Thick As a a Guide for Women
    A flexible cystoscope is a thin telescope which is passed Cystoscopy into the bladder via the urethra, it is about as thick as a A Guide for Women pencil. As the cystoscope is flexible, it usually passes easily 1. What is a Cystoscopy? moved so the doctor can look at all the inside lining of the along the curves of the urethra. The flexible tip can also be 2. Why is a Cystoscopy performed? bladder and the opening of the ureters. 3. Preparation for the test 4. About the test 5. Are there any risks? A rigid cystoscope is a shorter rigid telescope, it allows 6. What to expect afterwards? a greater variety of devices to pass down side channels so that the doctor can for example take samples or inject into the bladder. Sometimes, it is necessary to perform a rigid What is a Cystoscopy? Cystoscopy is the name for a procedure allowing a doctor to look into your bladder and urethra with a special telescope cystoscopy at a later date after a flexible cystoscopy. called a cystoscope. Preparation for the test If you are having an outpatient procedure in most cases you When you have a bladder problem, your doctor may use a will be able to eat and drink normally prior to the test. If you cystoscope to see inside your bladder and urethra. The ure- are having general anesthesia, you should refrain from eat- thra is the tube that carries urine from the bladder to the ing and drinking for 6 to 8 hours prior to your cystoscopy.
    [Show full text]
  • Study Guide Medical Terminology by Thea Liza Batan About the Author
    Study Guide Medical Terminology By Thea Liza Batan About the Author Thea Liza Batan earned a Master of Science in Nursing Administration in 2007 from Xavier University in Cincinnati, Ohio. She has worked as a staff nurse, nurse instructor, and level department head. She currently works as a simulation coordinator and a free- lance writer specializing in nursing and healthcare. All terms mentioned in this text that are known to be trademarks or service marks have been appropriately capitalized. Use of a term in this text shouldn’t be regarded as affecting the validity of any trademark or service mark. Copyright © 2017 by Penn Foster, Inc. All rights reserved. No part of the material protected by this copyright may be reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, or by any information storage and retrieval system, without permission in writing from the copyright owner. Requests for permission to make copies of any part of the work should be mailed to Copyright Permissions, Penn Foster, 925 Oak Street, Scranton, Pennsylvania 18515. Printed in the United States of America CONTENTS INSTRUCTIONS 1 READING ASSIGNMENTS 3 LESSON 1: THE FUNDAMENTALS OF MEDICAL TERMINOLOGY 5 LESSON 2: DIAGNOSIS, INTERVENTION, AND HUMAN BODY TERMS 28 LESSON 3: MUSCULOSKELETAL, CIRCULATORY, AND RESPIRATORY SYSTEM TERMS 44 LESSON 4: DIGESTIVE, URINARY, AND REPRODUCTIVE SYSTEM TERMS 69 LESSON 5: INTEGUMENTARY, NERVOUS, AND ENDOCRINE S YSTEM TERMS 96 SELF-CHECK ANSWERS 134 © PENN FOSTER, INC. 2017 MEDICAL TERMINOLOGY PAGE III Contents INSTRUCTIONS INTRODUCTION Welcome to your course on medical terminology. You’re taking this course because you’re most likely interested in pursuing a health and science career, which entails ­proficiency­in­communicating­with­healthcare­professionals­such­as­physicians,­nurses,­ or dentists.
    [Show full text]
  • Oncology 101 Dictionary
    ONCOLOGY 101 DICTIONARY ACUTE: Symptoms or signs that begin and worsen quickly; not chronic. Example: James experienced acute vomiting after receiving his cancer treatments. ADENOCARCINOMA: Cancer that begins in glandular (secretory) cells. Glandular cells are found in tissue that lines certain internal organs and makes and releases substances in the body, such as mucus, digestive juices, or other fluids. Most cancers of the breast, pancreas, lung, prostate, and colon are adenocarcinomas. Example: The vast majority of rectal cancers are adenocarcinomas. ADENOMA: A tumor that is not cancer. It starts in gland-like cells of the epithelial tissue (thin layer of tissue that covers organs, glands, and other structures within the body). Example: Liver adenomas are rare but can be a cause of abdominal pain. ADJUVANT: Additional cancer treatment given after the primary treatment to lower the risk that the cancer will come back. Adjuvant therapy may include chemotherapy, radiation therapy, hormone therapy, targeted therapy, or biological therapy. Example: The decision to use adjuvant therapy often depends on cancer staging at diagnosis and risk factors of recurrence. BENIGN: Not cancerous. Benign tumors may grow larger but do not spread to other parts of the body. Also called nonmalignant. Example: Mary was relieved when her doctor said the mole on her skin was benign and did not require any further intervention. BIOMARKER TESTING: A group of tests that may be ordered to look for genetic alterations for which there are specific therapies available. The test results may identify certain cancer cells that can be treated with targeted therapies. May also be referred to as genetic testing, molecular testing, molecular profiling, or mutation testing.
    [Show full text]
  • Inspection Examination of the Ureter and Biopsy Procedure Specific
    PATIENT INFORMATION Inspection/examination of the ureter & biopsy : procedure-specific information What is the evidence base for this information? This leaflet includes advice from consensus panels, the British Association of Urological Surgeons, the Department of Health and evidence-based sources; it is, therefore, a reflection of best practice in the UK. It is intended to supplement any advice you may already have been given by your GP or other healthcare professionals. Alternative treatments are outlined below and can be discussed in more detail with your Urologist or Specialist Nurse. What does the procedure involve? Examination of the ureter and kidney ± biopsy, with possible placement of a plastic tube or stent. This procedure usually includes cystoscopy and x-ray screening What are the alternatives to this procedure? Open surgery, other X-ray investigations or further observation Source: Urology Reference No: 5611-1 Issue date: 27.06.2014 Review date: 27.06.2016 Page 1 of 5 What should I expect before the procedure? You will usually be admitted on the same day as your surgery. You will normally receive an appointment for pre-assessment, approximately 14 days before your admission, to assess your general fitness, to screen for the carriage of MRSA and to perform some baseline investigations. After admission, you will be seen by members of the medical team which may include the Consultant, Specialist Registrar, House Officer and your named nurse. You will be asked not to eat or drink for 6 hours before surgery and, immediately before the operation, you may be given a pre-medication by the anaesthetist which will make you dry- mouthed and pleasantly sleepy.
    [Show full text]
  • Gastroesophageal Reflux Disease (GERD)
    Guidelines for Clinical Care Quality Department Ambulatory GERD Gastroesophageal Reflux Disease (GERD) Guideline Team Team Leader Patient population: Adults Joel J Heidelbaugh, MD Objective: To implement a cost-effective and evidence-based strategy for the diagnosis and Family Medicine treatment of gastroesophageal reflux disease (GERD). Team Members Key Points: R Van Harrison, PhD Diagnosis Learning Health Sciences Mark A McQuillan, MD History. If classic symptoms of heartburn and acid regurgitation dominate a patient’s history, then General Medicine they can help establish the diagnosis of GERD with sufficiently high specificity, although sensitivity Timothy T Nostrant, MD remains low compared to 24-hour pH monitoring. The presence of atypical symptoms (Table 1), Gastroenterology although common, cannot sufficiently support the clinical diagnosis of GERD [B*]. Testing. No gold standard exists for the diagnosis of GERD [A*]. Although 24-hour pH monitoring Initial Release is accepted as the standard with a sensitivity of 85% and specificity of 95%, false positives and false March 2002 negatives still exist [II B*]. Endoscopy lacks sensitivity in determining pathologic reflux but can Most Recent Major Update identify complications (eg, strictures, erosive esophagitis, Barrett’s esophagus) [I A]. Barium May 2012 radiography has limited usefulness in the diagnosis of GERD and is not recommended [III B*]. Content Reviewed Therapeutic trial. An empiric trial of anti-secretory therapy can identify patients with GERD who March 2018 lack alarm or warning symptoms (Table 2) [I A*] and may be helpful in the evaluation of those with atypical manifestations of GERD, specifically non-cardiac chest pain [II B*]. Treatment Ambulatory Clinical Lifestyle modifications.
    [Show full text]
  • Biopsy and Cytology
    BIOPSY AND CYTOLOGY Biopsy • Definition • Biopsy is the removal of a sample of living tissue for laboratory examination. • Rationale • It is a dentist’s obligation to make a diagnosis, or see that a diagnosis is made, of any pathological lesion in the mouth. • Some lesions can be diagnosed clinically, and biopsy is not required e.g. recurrent aphthous ulceration, Herpes simplex lesions. • Many lesions cannot be positively diagnosed clinically and should be biopsied – or in some cases smeared for cytopathologic examination. • Pitfalls of relying on a strictly clinical diagnosis are numerous: • A loose tooth may be due to a malignancy, not to advance periodontal disease. • What appears to be a dentigerous cyst clinically e.g. may be an odontogenic tumor. • Harmless looking white patches may be malignant or premalignant. Red patches are even more important. • It has been said that “any tissue which has been removed surgically is worth examining microscopically” • Yet dentists in general do not follow this rule. • However, there are some tissues e.g. gingivectomies, where every specimen need not be submitted. • While cancer is one disease in which biopsy is important, there are many other lesions in which this procedure is useful. • It is a sensitive diagnostic tool. CDE (Oral Pathology and Oral Medicine) 1 BIOPSY AND CYTOLOGY • Methods of Biopsy • Excisional – entire lesion is removed, along with a margin of normal tissue. • Incisional – representative portion of the lesion is removed, along with a margin of normal tissue. • Electrocautery – tends to damage tissue and make interpretation difficult. • Punch • Needle and aspiration • Curettage – intraosseous • Exfoliative cytology. • The Oral Biopsy – Avoidable Pitfalls.
    [Show full text]
  • Biopsy Features in Inflammatory Bowel Disease Gut: First Published As 10.1136/Gut.35.7.961 on 1 July 1994
    Gut 1994; 35: 961-968 961 Observer variation and discriminatory value of biopsy features in inflammatory bowel disease Gut: first published as 10.1136/gut.35.7.961 on 1 July 1994. Downloaded from A Theodossi, D J Spiegelhalter, J Jass, J Firth, M Dixon, M Leader, D A Levison, R Lindley, I Filipe, A Price, N A Shepherd, S Thomas, H Thompson Abstract macroscopic and biopsy material taken from If skilled histopathologists disagree over patients with inflammatory bowel disease. the same biopsy specimen, at least one They reported the percentage agreement, but must have an incorrect interpretation. did not take into account the proportion of Thus, disagreement is associated with, observed agreement due to chance alone. although not the cause of, diagnostic Surawicz and Belic6 and Allison et al 7 con- error. The present study aimed to sidered the value of features in discriminating determine the magnitude of variation acute self limited colitis from idiopathic among 10 observers with a special interest inflammatory bowel disease, and reported both in gastrointestinal histopathology. They definitions and simple percentage agreement independently interpreted the same on selected features. biopsy specimens for morphological We believe that histopathology provides an features which may discriminate between important contribution to the diagnosis of patients with Crohn's disease and ulcera- inflammatory bowel disease. The aim of the tive colitis and normal subjects. Thirty of present study therefore was to determine the 41 features had agreement measures reliability of the information obtained from significantly better than expected by colorectal mucosal biopsy specimens by chance (p<005). The range of agreement assessing the magnitude of variation among 10 in the 45 observer pairs over the final histopathologists with a special interest in diagnosis was 65-76%.
    [Show full text]
  • AASLD Position Paper : Liver Biopsy
    AASLD POSITION PAPER Liver Biopsy Don C. Rockey,1 Stephen H. Caldwell,2 Zachary D. Goodman,3 Rendon C. Nelson,4 and Alastair D. Smith5 This position paper has been approved by the AASLD and College of Cardiology and the American Heart Associa- represents the position of the association. tion Practice Guidelines3).4 Introduction Preamble Histological assessment of the liver, and thus, liver bi- These recommendations provide a data-supported ap- opsy, is a cornerstone in the evaluation and management proach. They are based on the following: (1) formal re- of patients with liver disease and has long been considered view and analysis of the recently published world to be an integral component of the clinician’s diagnostic literature on the topic; (2) American College of Physi- armamentarium. Although sensitive and relatively accu- cians Manual for Assessing Health Practices and De- rate blood tests used to detect and diagnose liver disease signing Practice Guidelines1; (3) guideline policies, have now become widely available, it is likely that liver including the AASLD Policy on the Development and biopsy will remain a valuable diagnostic tool. Although Use of Practice Guidelines and the American Gastro- histological evaluation of the liver has become important enterological Association Policy Statement on Guide- in assessing prognosis and in tailoring treatment, nonin- lines2; and (4) the experience of the authors in the vasive techniques (i.e., imaging, blood tests) may replace specified topic. use of liver histology in this setting, particularly with re- Intended for use by physicians, these recommenda- gard to assessment of the severity of liver fibrosis.5,6 Sev- tions suggest preferred approaches to the diagnostic, ther- eral techniques may be used to obtain liver tissue; a table apeutic, and preventive aspects of care.
    [Show full text]